Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Titel:
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Auteur:
Motzer, Robert J Rini, Brian I McDermott, David F Arén Frontera, Osvaldo Hammers, Hans J Carducci, Michael A Salman, Pamela Escudier, Bernard Beuselinck, Benoit Amin, Asim Porta, Camillo George, Saby Neiman, Victoria Bracarda, Sergio Tykodi, Scott S Barthélémy, Philippe Leibowitz-Amit, Raya Plimack, Elizabeth R Oosting, Sjoukje F Redman, Bruce Melichar, Bohuslav Powles, Thomas Nathan, Paul Oudard, Stéphane Pook, David Choueiri, Toni K Donskov, Frede Grimm, Marc-Oliver Gurney, Howard Heng, Daniel Y C Kollmannsberger, Christian K Harrison, Michael R Tomita, Yoshihiko Duran, Ignacio Grünwald, Viktor McHenry, M Brent Mekan, Sabeen Tannir, Nizar M